139 related articles for article (PubMed ID: 26540493)
1. Trastuzumab and Cardiac Outcomes in Breast Cancer: A Story We Know by Heart?
Milano G; Chamorey E; Ferrero JM
JAMA Oncol; 2016 Jan; 2(1):21-2. PubMed ID: 26540493
[No Abstract] [Full Text] [Related]
2. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
Dang C; Guo H; Najita J; Yardley D; Marcom K; Albain K; Rugo H; Miller K; Ellis M; Shapira I; Wolff AC; Carey LA; Moy B; Groarke J; Moslehi J; Krop I; Burstein HJ; Hudis C; Winer EP; Tolaney SM
JAMA Oncol; 2016 Jan; 2(1):29-36. PubMed ID: 26539793
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy.
Upshaw JN; Finkelman B; Hubbard RA; Smith AM; Narayan HK; Arndt L; Domchek S; DeMichele A; Fox K; Shah P; Clark A; Bradbury A; Matro J; Adusumalli S; Carver JR; Ky B
JACC Cardiovasc Imaging; 2020 Jan; 13(1 Pt 2):198-210. PubMed ID: 31542526
[TBL] [Abstract][Full Text] [Related]
4. Association between clinical risk factors and left ventricular function in patients with breast cancer following chemotherapy.
Yamashita K; Tanaka H; Hatazawa K; Tanaka Y; Sumimoto K; Shono A; Suzuki M; Yokota S; Suto M; Mukai J; Takada H; Matsumoto K; Minami H; Hirata KI
Int J Cardiovasc Imaging; 2021 Jan; 37(1):197-205. PubMed ID: 32860123
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy.
Huang G; Zhai J; Huang X; Zheng D
Medicine (Baltimore); 2018 Sep; 97(38):e12447. PubMed ID: 30235730
[TBL] [Abstract][Full Text] [Related]
6. Cardiac dysfunction in cancer patients receiving paclitaxel.
Valdés Olmos RA; ten Bokkel Huinink WW; Hoefnagel CA
Eur J Nucl Med; 1998 Apr; 25(4):446-7. PubMed ID: 9643974
[No Abstract] [Full Text] [Related]
7. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction.
Fei HW; Ali MT; Tan TC; Cheng KH; Salama L; Hua L; Zeng X; Halpern EF; Taghian A; MacDonald SM; Scherrer-Crosbie M
Echocardiography; 2016 Apr; 33(4):519-26. PubMed ID: 26992012
[TBL] [Abstract][Full Text] [Related]
8. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
9. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
[TBL] [Abstract][Full Text] [Related]
10. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
[TBL] [Abstract][Full Text] [Related]
11. Small benefits in trastuzumab-related cardiotoxicity.
Das M
Lancet Oncol; 2017 Jan; 18(1):e5. PubMed ID: 27956153
[No Abstract] [Full Text] [Related]
12. Retrospective analysis of cardiac tolerability of concurrent administration of trastuzumab and anthracycline-based regimen for breast cancer, to address one-year-term issues in LVEF.
Watanabe N; Otsuka S; Sasaki Y; Yuasa T; Shimada K
Breast Dis; 2015; 35(4):253-61. PubMed ID: 26518668
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity of trastuzumab in clinical practice.
McArthur HL; Chia S
N Engl J Med; 2007 Jul; 357(1):94-5. PubMed ID: 17611218
[No Abstract] [Full Text] [Related]
14. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
[TBL] [Abstract][Full Text] [Related]
15. Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study.
Pivot X; Suter T; Nabholtz JM; Pierga JY; Espie M; Lortholary A; Khayat D; Pauporte I; Romieu G; Kramar A; Fumoleau P
Eur J Cancer; 2015 Sep; 51(13):1660-6. PubMed ID: 26163096
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity.
Nisticò C; Bria E; Vaccaro V; Cuppone F; Fornier M; Sperduti I; Carpino A; Izzo F; Tropea F; Cognetti F; Terzoli E
Anticancer Drugs; 2009 Feb; 20(2):109-14. PubMed ID: 19209027
[TBL] [Abstract][Full Text] [Related]
17. Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors.
Clifton GT; Peace KM; Holmes JP; Vreeland TJ; Hale DF; Herbert GS; Litton JK; Murthy RK; Lukas J; Peoples GE; Mittendorf Elizabeth A
Clin Immunol; 2019 Apr; 201():48-54. PubMed ID: 30817999
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
19. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.
Kelly H; Kimmick G; Dees EC; Collichio F; Gatti L; Sawyer L; Ivanova A; Dressler L; Graham ML; Carey LA
Clin Breast Cancer; 2006 Aug; 7(3):237-43. PubMed ID: 16942640
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.
Schneeweiss A; Chia S; Hickish T; Harvey V; Eniu A; Waldron-Lynch M; Eng-Wong J; Kirk S; Cortés J
Eur J Cancer; 2018 Jan; 89():27-35. PubMed ID: 29223479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
